Contexium

Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service is a published development and funding opportunity on Contexium. The donor or funder is NHS England. Project location(s): United Kingdom. Applications close on 08 Jul 2026. Budget: 26,136,000 GBP. Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenou…

Opportunity overview

Project name
Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service
NHS England logo
NHS England
Donor
NHS England

Key details

Opportunity start date
Opportunity end date
Proposed project start date
Project location(s)
United Kingdom
Budget
26,136,000
Currency
UK Pound Sterling

Summary

Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and...

Frequently asked questions

What is Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service?

Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service is a published development and funding opportunity on Contexium. The donor or funder is NHS England. Project location(s): United Kingdom. Applications close on 08 Jul 2026. Budget: 26,136,000 GBP. Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenou…

Who is funding Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service?

Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service is funded by NHS England.

When is the deadline to apply for Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service?

The application deadline is 08 Jul 2026 12:00 (UTC).

Where will the Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service project take place?

The project location(s) are: United Kingdom.

What is the budget for Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service?

The available budget is 26,136,000 GBP.

How can I apply for Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service?

Create a free Contexium account to view the full opportunity details and submit an application via the marketplace.